Associated Genetic Biomarkers
Cyclin B2 (CCNB2) is a gene that encodes a member of the cyclin family that functions as a regulator of cyclin-dependent kinases (CDKs). Cyclin B2 is involved in the regulation of the cell cycle and associates with the Golgi region. Missense mutations, nonsense mutations, silent mutations, nonstop extensions, and frameshift insertions are observed in cancers such as bone cancer, endometrial cancer, and skin cancer.
CCNB2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CCNB2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with CCNB2 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CCNB2 Mutation .
Abemaciclib is the most frequent therapy in trials with CCNB2 as an inclusion criteria .
Significance of CCNB2 in Diseases
Malignant Solid Tumor +
CCNB2 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNB2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.